The strategic review process (MTS Health Partners) creates binary optionality — a sale or partnership could provide a premium, but the cash runway is tight (~4 months). The Nov 14 PDUFA date is the next major catalyst. Monitor for any pre-announcement of a deal or financing before cash runs out.
Price Chart
Executive Summary
BioXcel Therapeutics reported Q1 2026 revenue of $206K (up 22.6% YoY from $168K) and a GAAP net loss of $12.7M ($0.54/share), wider than the $7.3M loss in Q1 2025. The FDA accepted the sNDA for IGALMI at-home use with a PDUFA date of Nov 14, 2026, and the company engaged MTS Health Partners to explore strategic options including a potential sale. Cash burn continues rapidly — cash dropped from $28.8M to $17.2M in the quarter, giving roughly 4 months of runway at current burn rates.
Key Financial Metrics
Key Facts
- FDA accepted sNDA for IGALMI at-home use; PDUFA date set for Nov 14, 2026
- Engaged MTS Health Partners to evaluate strategic options including sale, merger, or collaboration
- Q1 2026 net revenue $206K vs $168K YoY (22.6% increase)
- Net loss widened to $12.7M from $7.3M in Q1 2025
- Cash and restricted cash fell to $17.2M from $28.8M at Dec 31, 2025 (burn ~$11.6M/quarter)
- Weighted average shares outstanding surged to 23.6M from 4.8M YoY (massive dilution)
- Net loss per share improved to -$0.54 from -$1.50 due to share count increase
- SG&A expenses rose to $7.2M from $5.7M due to higher professional fees for strategic review
- R&D expenses decreased to $3.0M from $4.6M as SERENITY Phase 3 trial completed
- Company remains in compliance with credit agreement covenants
Financial Impact
Cash burn of ~$11.6M/quarter with $17.2M remaining — runway to approximately Q3 2026 without additional financing or strategic transaction
Risk Factors
- Cash runway only ~4 months at current burn rate — likely needs financing or strategic deal before Q3 2026
- Massive dilution from 4.8M to 23.6M shares outstanding YoY
- IGALMI current revenue ($206K/quarter) is de minimis and declining in absolute terms from prior year levels
- Strategic review may not result in any transaction
- sNDA approval is not guaranteed; PDUFA date is Nov 14, 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-061773 |
| Document: tm2614679d1_8k.htm | 0001104659-26-061773 |
| Document: 0001104659-26-061773-index-headers.html | 0001104659-26-061773 |
| Document: 0001104659-26-061773-index.html | 0001104659-26-061773 |
| Document: 0001104659-26-061773.txt | 0001104659-26-061773 |
| 8-K Data (Synthetic) | 0001104659-26-061773 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $0.1370 | awaiting T+60 | — | — |
Aug 28, 2026 8w ago | Press Release | $0.1814 | awaiting T+60 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.7422 | awaiting T+60 | — | — |
Aug 11, 2026 10w ago | 8-K | $0.9320 | awaiting T+60 | — | — |
Aug 3, 2026 12w ago | 8-K | $0.8480 | awaiting T+60 | — | — |
Jul 6, 2026 16w ago | 8-K | $1.10 | awaiting T+60 | — | — |
May 22, 2026 22w ago | Insider Cluster | $1.22 $0.8274 | ▲ +32.18% | ▲ +34.91% | — |
May 20, 2026 22w ago | 144 | $1.14 $0.8900 | ▼ −21.93% | ▼ −26.23% | — |
May 15, 2026 23w ago | 8-K | $1.14 $0.9319 | ▼ −18.25% | ▼ −22.77% | — |
May 15, 2026 23w ago | Press Release | $1.14 $0.9319 | ▲ +18.25% | ▲ +22.77% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers